- Home
- Solutions
- By Services
- Ophthalmic Disease Diagnostics Development Services
As a research services provider, Protheragen understands the critical importance of early and accurate detection of ophthalmic diseases in driving the development of innovative therapeutics. We are committed to providing our customers with a one-stop ophthalmic disease therapy development service.
Ophthalmic disease diagnostics development encompasses preclinical research and translational efforts focused on creating accurate, sensitive, and specific tools to detect, classify, and monitor ocular disorders across all anatomical segments of the eye. These diagnostic tools target conditions ranging from genetic and autoimmune ophthalmopathies to neoplastic, infectious, and degenerative diseases, enabling early intervention, treatment stratification, and efficacy assessment. Preclinical development in this field prioritizes validating diagnostic biomarkers, optimizing detection technologies, and evaluating assay performance in disease-relevant models—all while ensuring compatibility with ocular physiology and clinical workflow before advancing to clinical validation.
The preclinical pipeline for ophthalmic diagnostics is defined by its focus on overcoming unique ocular challenges, including the need for non-invasive or minimally invasive sampling, the ability to penetrate ocular barriers for deep-tissue biomarker detection, and the requirement for high specificity to distinguish overlapping disease phenotypes. Core objectives include identifying disease-specific biomarkers (genetic variants, proteins, metabolites, or cellular signatures), optimizing detection limits to enable early-stage diagnosis, and integrating diagnostic tools with therapeutic development to support companion diagnostic (CDx) strategies. Preclinical studies integrate in vitro biomarker validation assays, ex vivo ocular tissue models, and in vivo disease models to generate data on assay sensitivity, specificity, reproducibility, and safety—critical for regulatory clearance and clinical adoption.
Fig.1 Ophthalmic technologies for ocular disease diagnostics. (Shi Y., et al., 2021)This development process is tailored to the heterogeneous nature of ophthalmic diseases, each requiring distinct diagnostic approaches. For example, genetic ophthalmopathies demand nucleic acid-based diagnostics to detect pathogenic variants, while degenerative conditions like age-related macular degeneration (AMD) rely on protein or metabolite biomarkers in ocular fluids. Preclinical validation prioritizes assessments of biomarker specificity to avoid cross-reactivity with healthy ocular tissues or comorbid conditions, as well as assay robustness under physiological conditions (e.g., tear film composition, vitreous humor viscosity). Rigorous preclinical testing also addresses the challenge of translating biomarker utility from animal models to humans, ensuring diagnostic tools recapitulate key clinical features of human disease and provide actionable insights for clinical decision-making.
Key methodologies in preclinical ophthalmic diagnostics development include biomarker discovery via omics technologies, assay optimization for ocular sample matrices (tears, aqueous humor, vitreous humor, or ocular tissues), and performance validation against gold-standard diagnostic methods. Preclinical studies must also evaluate sample collection feasibility, as ocular samples are often limited in volume and require specialized handling to preserve biomarker integrity. For CDx development, preclinical work aligns diagnostic performance with therapeutic response, ensuring the tool can accurately identify patient populations most likely to benefit from a specific therapy—an essential component of personalized ophthalmic care.
Preclinical diagnostics development also emphasizes compatibility with existing clinical imaging or testing platforms, as well as scalability for widespread use. This includes optimizing diagnostic tools for integration with optical coherence tomography (OCT), fundus photography, or electroretinography (ERG), and ensuring assays can be adapted for point-of-care (POC) settings to improve access in resource-limited environments. By addressing these preclinical considerations, developers can accelerate the translation of diagnostic tools from the lab to the clinic, reducing diagnostic delays and improving outcomes for patients with vision-threatening ocular diseases.
Molecular Diagnostics
Molecular diagnostics are pivotal in the advancement of ophthalmic diseases diagnostics. Innovations like polymerase chain reaction (PCR) and next-generation sequencing (NGS) enable the identification of precise genetic mutations linked to hereditary eye disorders. These cutting-edge technologies have transformed the landscape of diagnosing conditions such as retinitis pigmentosa and Leber's congenital amaurosis.
Imaging Technologies
Advanced imaging technologies are essential in ophthalmic diagnostics. Optical coherence tomography (OCT) provides high-resolution cross-sectional images of the retina, aiding in the diagnosis of conditions like macular degeneration and glaucoma. Fundus autofluorescence (FAF) imaging offers insights into retinal pigment epithelium dysfunction, particularly in diseases like age-related macular degeneration.
At Protheragen, we offer a comprehensive suite of services to support the development of cutting-edge ophthalmic disease diagnostics. Our specialized expertise encompasses the following key areas:
Protheragen provides end-to-end biomarker discovery and validation services for ophthalmic diseases, leveraging omics technologies and disease-relevant models. This includes unbiased biomarker screening via NGS (genomic/transcriptomic), MS-based proteomics/metabolomics, and high-throughput immunoassays to identify candidate biomarkers in ocular fluids (tears, aqueous humor, vitreous humor) and tissues. We offer rigorous validation assays to confirm biomarker specificity and sensitivity, including qPCR/dPCR for genetic variants, ELISA/multiplex bead assays for proteins, and targeted MS for metabolites. Clients can access support for biomarker qualification, including correlation with disease severity, progression, and therapeutic response in preclinical models, to ensure clinical relevance and regulatory acceptability.
We specialize in developing and optimizing diagnostic assays tailored to ophthalmic sample matrices and disease-specific requirements. For nucleic acid-based assays, we optimize qPCR/dPCR primer/probe design, NGS library preparation, and target enrichment protocols to enhance sensitivity for low-abundance variants in small-volume ocular samples. For protein/metabolite assays, we refine sample preparation workflows to minimize matrix interference and improve detection limits, optimizing ELISA conditions, MS parameters, and multiplex panel design. We also evaluate assay robustness under physiological conditions (temperature, pH, sample storage) and optimize for scalability, supporting transition from preclinical research to clinical testing. Additionally, we offer assay cross-validation against gold-standard methods to ensure accuracy and reproducibility.
Protheragen delivers preclinical validation services for imaging-based ophthalmic diagnostics, including OCTA, confocal microscopy, FISH, and nanotechnology-enabled imaging agents. We evaluate imaging tool performance in disease models (e.g., AMD, DR, uveitis, ocular tumors) by correlating imaging findings with histopathological analysis, biomarker expression, and functional endpoints (ERG, visual acuity). For targeted imaging agents, we assess binding specificity, tissue penetration, and signal-to-noise ratio in ex vivo ocular tissues and in vivo models, optimizing agent design to enhance target engagement. We also quantify imaging-derived biomarkers (vessel density, cellular infiltration, tumor size) to establish correlation with disease progression and therapeutic response, supporting clinical endpoint selection.
We support the development of CDx tools aligned with ophthalmic therapeutics, ensuring diagnostic performance correlates with therapeutic efficacy in preclinical models. This includes identifying predictive biomarkers that stratify patient populations by treatment response, developing assays to detect these biomarkers, and validating assay performance in conjunction with therapeutic testing. We evaluate CDx-therapy alignment via preclinical efficacy studies, measuring biomarker status alongside treatment outcomes (tumor regression, inflammation reduction, vision preservation) to confirm predictive value. Clients can access support for integrating CDx development with therapeutic pipelines, ensuring regulatory compatibility and streamlined clinical translation.
We conduct comprehensive preclinical performance and safety assessments to support regulatory submission of ophthalmic diagnostics. Performance testing includes evaluation of sensitivity, specificity, precision, accuracy, and reproducibility across multiple preclinical models and sample batches. We assess assay interference from comorbid conditions, medications, and sample handling variables to ensure robustness in clinical settings. For imaging agents and invasive diagnostics, we perform safety testing to evaluate ocular irritation, tissue toxicity, and immunogenicity in in vivo models, adhering to GLP standards. All studies generate detailed reports with statistically robust data, supporting regulatory clearance and clinical trial design.
Protheragen offers specialized services to characterize ophthalmic sample matrices and optimize diagnostic compatibility. We analyze the composition of tears, aqueous humor, vitreous humor, and ocular tissues (retina, uvea, cornea) to identify matrix components that may interfere with diagnostic assays, developing mitigation strategies (sample dilution, purification, additive use) to improve assay performance. We evaluate sample stability under different storage and transport conditions, establishing protocols to preserve biomarker integrity and assay accuracy. Additionally, we quantify biomarker abundance across sample types and disease stages, guiding sample collection strategy and assay design for optimal clinical utility.
Protheragen is committed to staying at the forefront of technological advancements, continuously investing in the latest diagnostic tools and analytical platforms to provide our clients with the most innovative solutions. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.